ASTRIS real world study of osimertinib in patients (pts) with EGFR T790M NSCLC: Efficacy analysis by tissue or plasma T790M test

被引：0
|
作者：
Freitas, H. C. [1 ]
Park, K. [2 ]
Kim, D-W. [3 ]
Tiseo, M. [4 ]
Hochmair, M. J. [5 ,6 ]
Chang, G-C. [7 ]
Shi, Y-K. [8 ,9 ]
Moran, T. [10 ]
Chen, Y. [11 ]
Laskin, J. [12 ]
Solomon, B. [13 ]
Miranda, M. [14 ]
Rigas, J. [15 ]
Cheema, P. K. [16 ]
Kim, S-W. [17 ]
机构：
[1] AC Camargo Canc Ctr, Clin Res Unit, Sao Paulo, Brazil
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Heamatol Oncol,Med, Seoul, South Korea
[3] Seoul Natl Univ Hosp, Dept Internal Med, Hematooncol, Seoul, South Korea
[4] Univ Hosp Parma, Med Oncol Unit, Parma, Italy
[5] Otto Wagner Hosp, Dept Resp & Crit Care Med, Resp Oncol Unit, Vienna, Austria
[6] Otto Wagner Hosp, Ludwig Boltzmann Inst COPD, Vienna, Austria
[7] Taichung Vet Gen Hosp, Dept Internal Med, Div Chest Med, Taichung, Taiwan
[8] Chinese Acad Med Sci, Natl Canc Ctr, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol, Beijing, Peoples R China
[9] Peking Union Med Coll, Beijing, Peoples R China
[10] ICO Badalona Hosp Germans Trias & Pujol, Med Oncol Serv, Barcelona, Spain
[11] Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan
[12] British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC, Canada
[13] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[14] AstraZeneca, Biometr & Informat Sci, Cambridge, England
[15] AstraZeneca, GMA Oncol TA, Gaithersburg, MD USA
[16] Univ Toronto, William Osler Hlth Syst, Med Oncol, Brampton, ON, Canada
[17] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
466O
引用
收藏
页码：149 / 149
页数：1
相关论文
共 50 条
  • [11] ASTRIS, a real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC): preliminary analysis of the Italian cohort
    Passaro, A.
    Metro, G.
    Tiseo, M.
    Migliorino, M. R.
    Santo, A.
    Sperandi, F.
    Maione, P.
    Puppo, G.
    Grossi, F.
    Parra, H. J. Soto
    Borra, G.
    Roca, E.
    Rocco, D.
    Stasi, I.
    Galetta, D.
    Carta, A. M.
    Milella, M.
    Fasola, G.
    Gebbia, V.
    Ferrari, S.
    De Marinis, F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [12] ASTRIS: A multicenter, real world treatment study of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC)
    Cheema, P. K.
    Chen, Y-M.
    de Marinis, F.
    Freitas, H. C.
    Kim, S-W.
    Milner, A.
    Provencio, M.
    Rigas, J.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [13] Intracranial Activity of Osimertinib in Naive EGFRm T790M(-) And Treated EGFRm T790M(+) NSCLC Patients with Asymptomatic Brain Metastases
    Peled, N.
    Nechushtan, H.
    Ilouze, M.
    Dudnik, E.
    Inbar, E.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2223 - S2223
  • [14] Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients
    Remon, Jordi
    Caramella, Caroline
    Joelet, Cecile
    Lacroix, Ludovic
    Lawson, Andrew
    Smalley, Sarah
    Howarth, Karen
    Gale, Davina
    Rosenfeld, Nitzan
    Green, Emma
    Plagnol, Vincent
    Planchard, David
    Bluthgen, Maria
    Gazzah, Annas
    Pannet, Chloe
    Nicotra, Claudio
    Soria, Jean-Charles
    Besse, Benjamin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1254 - S1255
  • [15] Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example
    Wei, Bing
    Zhao, Chengzhi
    Li, Jun
    Zhao, Jiuzhou
    Ren, Pengfei
    Yang, Ke
    Yan, Chi
    Sun, Rui
    Ma, Jie
    Guo, Yongjun
    MOLECULAR ONCOLOGY, 2019, 13 (05) : 1226 - 1234
  • [16] Osimertinib Depletes EGFR T790M in the Spinal Fluid of Patients with Carcinomatous Meningitis of Lung Adenocarcinoma Harboring De Novo EGFR T790M
    Senoo, Satoru
    Ohashi, Kadoaki
    Nishii, Kazuya
    Hara, Naofumi
    Kano, Hirohisa
    Ninomiya, Kiichiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : E140 - E142
  • [17] Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation
    Watanabe, Kana
    Saito, Ryota
    Miyauchi, Eisaku
    Nagashima, Hiromi
    Nakamura, Atsushi
    Sugawara, Shunichi
    Tanaka, Nobuyuki
    Terasaki, Hiroshi
    Fukuhara, Tatsuro
    Maemondo, Makoto
    CANCERS, 2023, 15 (17)
  • [18] A Prospective Observational Study of Osimertinib Using Plasma Concentrations in NSCLC With Acquired EGFR T790M Mutation
    Nakagawa, T.
    Fukuhara, T.
    Imai, K.
    Igusa, R.
    Yokota, H.
    Watanabe, K.
    Suzuki, A.
    Morita, M.
    Inoue, A.
    Miura, M.
    Minamiya, Y.
    Maemondo, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S953 - S954
  • [19] Association between BIM Deletion Polymorphism and Efficacy of Osimertinib in Advanced EGFR T790M NSCLC Patients
    Li, X.
    Zhang, D.
    Wang, R. Z.
    Li, B.
    Guo, M.
    Zou, B.
    Yu, J.
    Wang, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E87 - E87
  • [20] Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study
    Schmid, S.
    Klingbiel, D.
    Aeppli, S.
    Britschgi, C.
    Gautschi, O.
    Pless, M.
    Rothschild, S.
    Wannesson, L.
    Janthur, W.
    Foerbs, D.
    Demmer, I.
    Jochum, W.
    Fruth, M.
    LUNG CANCER, 2019, 130 : 149 - 155
12345